Loading clinical trials...

Functional MRI for Monitoring Progression and Assessing Trends in ILD | Clinical Trials | Clareo Health

RECRUITINGNA

Functional MRI for Monitoring Progression and Assessing Trends in ILD

Functional Magnetic Resonance Imaging of the Lung to Detect Regional Reversibility and Progression in Interstitial Lung Disease

NCT07300696•University Hospital Heidelberg

View on ClinicalTrials.gov

Summary

The main objective of this study is to investigate the utility of functional MRI to differentiate, characterize, and monitor subgroups of ILD. This can be broken down into three specific objectives: Determine if ILD features observed on high-resolution computed tomography (HRCT), such as ground glass opacities (GGO), are functionally different. Analyse MRI metrics within each subgroup to determine whether these metrics distinguish different ILDs. Assess MRI metrics longitudinally to see if these parameters change with disease progression, stability, or reversibility.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Clinical indication for a routine HRCT because of either newly diagnosed idiopathic pulmonary fibrosis (IPF) or hypersensitivity pneumonitis (HP) or idiopathic non-specific interstitial pneumonia (iNSIP), suspected diagnosis, or follow-up
•Capacity to consent
•Ability to participate fully in the study (defined by the ability to lie still for the duration of imaging)

Exclusion Criteria

•Pregnancy and breast feeding
•Persons under the age of 18 and persons not able to give informed consent
•Any medical conditions that could hinder the ability to adhere to the protocol
•Any MRI contraindication, including previous allergic reactions to Gd-based MRI contrast material and renal dysfunction (eGFR \< 30 ml min/1,73 m2)

Locations (2)

Thoraxklink Heidelberg - Universitätsklinikum Heidelberg

Heidelberg, Germany

Universitätsklinikum Schleswig-Holstein, Campus Kiel

Kiel, Germany

Key Dates

Start Date

November 20, 2025

Primary Completion Date

February 1, 2027

Completion Date

July 1, 2027

Last Updated

December 24, 2025

Enrollment

200

ESTIMATED participants

Conditions

Interstitial Lung Diseases (ILD)

Interventions

Lung MRI Protocol with Functional and Contrast-Enhanced Sequences

DIAGNOSTIC_TEST

Treatable Traits in Interstitial Lung Disease

NCT06626438

Interstitial Lung Diseases (ILD)

View study

RECRUITING

Exercise Capacity, Muscle Oxygenation, and Physical Activity Between Patients With Interstitial Lung Disease

NCT06948942

Interstitial Lung Diseases (ILD)Healthy Individuals+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 24, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Functional MRI for Monitoring Progression and Assessing Trends in ILD

Inclusion Criteria

Exclusion Criteria

Treatable Traits in Interstitial Lung Disease

Exercise Capacity, Muscle Oxygenation, and Physical Activity Between Patients With Interstitial Lung Disease

Diagnostic Yield and Safety of Lung Biopsy Techniques in Interstitial Lung Diseases